Für diese Kanzlei können nur begrenzte Informationen angezeigt werden. Für die folgenden Kanzleien werden vollständigere Informationen angezeigt:

Skadden, Arps, Slate, Meagher & Flom LLP advises life sciences clients on major M&A, with notable strength in acquisitions and dispositions, corporate restructurings, and joint ventures. The firm also handles litigation related to Medicaid, Medicare and insurance fraud, the False Claims Act,  mass torts, and securities, as well as Congressional investigations under the Foreign Corrupt Practices Act. On the regulatory side, it provides FDA regulatory diligence in connection with acquisitions, divestitures, financing, and investments, along with guidance on compliance and corporate governance. Also in Boston, Laura Knoll focuses on M&A and general corporate matters, including shareholder activism defense and securities compliance. Graham Robinson has left the firm.
Legal 500 redaktioneller Kommentar

Kernmandanten

  • Ambrx Biopharma, Inc.
  • Aspen Technology, Inc.

Highlight-Mandate

  • Represented a special committee of the board of directors of R1 RCM Inc. in its acquisition by investment funds at an enterprise value of $8.9 billion.
  • Advised Mirati Therapeutics, Inc. on its acquisition by Bristol Myers Squibb (BMS), which is now a wholly owned subsidiary of the company for a total equity value of $4.8 billion.